Trial Profile
A study evaluating benefit-risk assessment of cladribine tablets using Multi-Criteria Decision Analysis (MCDA) for patients with relapsing multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors EMD Serono
- 29 Jul 2018 New trial record
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology